Akèy › Lupus
Etid klinik pou Lupus ap rekrite nan Etazini
73 etid pou Lupus ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY18 etid
- Houston, TX13 etid
- Durham, NC12 etid
- Miami, FL10 etid
- Washington, DC10 etid
- Tampa, FL9 etid
- Philadelphia, PA9 etid
- Clearwater, FL8 etid
- Chicago, IL8 etid
- Boston, MA8 etid
- Santa Monica, CA8 etid
- Los Angeles, CA8 etid
- Memphis, TN7 etid
- Plantation, FL7 etid
- Buena Park, CA7 etid
- Charlotte, NC7 etid
- San Diego, CA7 etid
- Oklahoma City, OK7 etid
- Aurora, CO6 etid
- Dallas, TX6 etid
- Hollywood, FL6 etid
- Cedar Rapids, IA6 etid
- Atlanta, GA6 etid
- Fullerton, CA5 etid
- Jackson, TN5 etid
- Cicero, IL5 etid
- Lake Charles, LA5 etid
- New Orleans, LA5 etid
- St. Louis, MO5 etid
- Syracuse, NY5 etid
- Orlando, FL5 etid
- Cleveland, OH5 etid
- Flint, MI4 etid
- Frisco, TX4 etid
- San Francisco, CA4 etid
- Charleston, SC4 etid
- Salt Lake City, UT4 etid
- Louisville, KY4 etid
- Kansas City, KS4 etid
- Phoenix, AZ4 etid
Pa eta
- Alabama5 etid
- Arizona7 etid
- Colorado8 etid
- Distrik Columbia5 etid
- Florid23 etid
- Georgia9 etid
- Illinois14 etid
- Indiana4 etid
- Iowa6 etid
- Kalifòni27 etid
- Kansas5 etid
- Kentucky4 etid
- Lwizyàn9 etid
- Maryland10 etid
- Massachusetts9 etid
- Michigan10 etid
- Minnesota5 etid
- Missouri8 etid
- Nebraska3 etid
- New Jersey6 etid
- New York26 etid
- North Carolina20 etid
- Ohio11 etid
- Oklahoma7 etid
- Pennsylvania14 etid
- South Carolina5 etid
- Tennessee13 etid
- Texas26 etid
- Utah4 etid
- Virginia3 etid
- Washington5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT06133972Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT05268289A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Ap rekriteFaz 2
Laj 18 a 74 · Tout sèks · Mizajou Oct 1, 2026 · NCT07409181An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 30, 2026 · NCT05835310Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Fanm · Mizajou Sep 28, 2026 · NCT05567198A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07607964CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Ap rekriteFaz 1/2
Laj 10 a 29 · Tout sèks · Mizajou Sep 24, 2026 · NCT06839976Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Anifrolumab Pregnancy Study
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Fanm · Mizajou Sep 18, 2026 · NCT07049653The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 18, 2026 · NCT05440422Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Sep 18, 2026 · NCT07201558Transcutaneous Vagus Nerve Stimulation in SLE
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06987565A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Ap rekriteFaz 2
Laj 16 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07328581Study of Systemic Lupus Erythematosus
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 3 a 120 · Tout sèks · Mizajou Sep 16, 2026 · NCT00001372Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
Ap rekriteFaz 4
Laj 18 a 130 · Fanm · Mizajou Sep 16, 2026 · NCT06594068HEALTH Home Urinalysis Testing
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07823478A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 15, 2026 · NCT06916806A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT07355218Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Sep 14, 2026 · NCT06975787A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Ap rekriteFaz 2
Laj 12 a 70 · Tout sèks · Mizajou Sep 14, 2026 · NCT07570862A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 11, 2026 · NCT07332481A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 10, 2026 · NCT06897930Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.